Browse > Article
http://dx.doi.org/10.4062/biomolther.2016.271

New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism  

Kim, Joo Hee (College of Pharmacy & Institute of Pharmaceutical Science and Technology, Ajou University)
Lim, Kyung-Min (College of Pharmacy, Ewha Womans University)
Gwak, Hye Sun (College of Pharmacy, Ewha Womans University)
Publication Information
Biomolecules & Therapeutics / v.25, no.5, 2017 , pp. 461-470 More about this Journal
Abstract
Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional anticoagulants have several limitations such as unpredictable pharmacologic and pharmacokinetic responses and various adverse effects including serious bleeding complications. New oral anticoagulants have recently emerged as an alternative because of their rapid onset/offset of action, predictable linear dose-response relationships and fewer drug interactions. However, they are still associated with problems such as bleeding, lack of reversal agents and standard laboratory monitoring. In an attempt to overcome these drawbacks, key steps of the hemostatic pathway are investigated as targets for anticoagulation. Here we reviewed the traditional and new anticoagulants with respect to their targets in the coagulation cascade, along with their therapeutic advantages and disadvantages. In addition, investigational anticoagulant drugs currently in the development stages were introduced.
Keywords
Anticoagulant; Vitamin K antagonist; Heparin; Venous thromboembolism;
Citations & Related Records
Times Cited By KSCI : 4  (Citation Analysis)
연도 인용수 순위
1 Amiral, J., Bridey, F., Wolf, M., Boyer-Neumann, C., Fressinaud, E., Vissac, A. M., Peynaud-Debayle, E., Dreyfus, M. and Meyer, D. (1995) Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. 73, 21-28.   DOI
2 Bates, S. M. and Weitz, J. I. (2000) The mechanism of action of thrombin inhibitors. J. Invasive Cardiol. 12 Suppl F, 27F-32.
3 Baumann Kreuziger, L. M., Keenan, J. C., Morton, C. T. and Dries, D. J. (2014) Management of the bleeding patient receiving new oral anticoagulants: A role for prothrombin complex concentrates. BioMed Res. Int. 2014, 583794.
4 Schmid, P., Fischer, A. G. and Wuillemin, W. A. (2009) Low-molecularweight heparin in patients with renal insufficiency. Swiss Med. Wkly 139, 438-452.
5 Schroeder, M., Hogwood, J., Gray, E., Mulloy, B., Hackett, A. M. and Johansen, K. B. (2011) Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Anal. Bioanal. Chem. 399, 763-771.   DOI
6 Short, N. J. and Connors, J. M. (2014) New oral anticoagulants and the cancer patient. Oncologist 19, 82-93.   DOI
7 Sie, P. (2016) Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. Drug Des. Devel. Ther. 10, 1683-1689.
8 Smith, S. A., Choi, S. H., Collins, J. N., Travers, R. J., Cooley, B. C. and Morrissey, J. H. (2012) Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 120, 5103-5110.   DOI
9 Verhamme, P., Pakola, S., Jensen, T. J., Berggren, K., Sonesson, E., Saint-Remy, J. M., Balchen, T., Belmans, A., Cahillane, G., Stassen, J. M., Peerlinck, K., Glazer, S. and Jacquemin, M. (2010) Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin. Ther. 32, 1205-1220.   DOI
10 Vavalle, J. P. and Cohen, M. G. (2012) The REG1 anticoagulation system: A novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome. Future Cardiol. 8, 371-382.   DOI
11 Verhoef, T. I., Redekop, W. K., Daly, A. K., van Schie, R. M., de Boer, A. and Maitland-van der Zee, A. H. (2014) Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. Br. J. Clin. Pharmacol. 77, 626-641.   DOI
12 Vincent, J. L., Ramesh, M. K., Ernest, D., LaRosa, S. P., Pachl, J., Aikawa, N., Hoste, E., Levy, H., Hirman, J., Levi, M., Daga, M., Kutsogiannis, D. J., Crowther, M., Bernard, G. R., Devriendt, J., Puigserver, J. V., Blanzaco, D. U, Esmon, C. T, Parrillo, J. E., Guzzi, L., Henderson, S. J., Pothirat, C., Mehta, P., Fareed, J., Talwar, D., Tsuruta, K., Gorelick, K. J., Osawa, Y. and Kaul, I. (2013) A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit. Care Med. 41, 2069-2079.   DOI
13 Vlasuk, G. P. and Rote, W. E. (2002) Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant. Trends Cardiovasc. Med. 12, 325-331.   DOI
14 Das, A. and Liu, D. (2015) Novel antidotes for target specific oral anticoagulants. Exp. Hematol. Oncol. 4, 25.   DOI
15 Chapin, J. C. and Hajjar, K. A. (2015) Fibrinolysis and the control of blood coagulation. Blood Rev. 29, 17-24.   DOI
16 Chow, F. S., Benincosa, L. J., Sheth, S. B., Wilson, D., Davis, C. B., Minthorn, E. A. and Jusko, W. J. (2002) Pharmacokinetic and pharmacodynamic modeling of humanized anti-factor IX antibody (SB 249417) in humans. Clin. Pharmacol. Ther. 71, 235-245.   DOI
17 Connolly, G. and Spyropoulos, A. C. (2013) Practical issues, limitations, and periprocedural management of the NOAC's. J. Thromb. Thrombolysis 36, 212-222.   DOI
18 Connors, J. M. (2015) Antidote for factor Xa anticoagulants. N. Engl. J. Med. 373, 2471-2472.   DOI
19 Coughlin, S. R. (1994) Thrombin receptor function and cardiovascular disease. Trends Cardiovasc. Med. 4, 77-83.   DOI
20 Dellinger, R. P. (2003) Inflammation and coagulation: Implications for the septic patient. Clin. Infect. Dis. 36, 1259-1265.   DOI
21 Dickinson, C. D. and Ruf, W. (1997) Active site modification of factor VIIa affects interactions of the protease domain with tissue factor. J. Biol. Chem. 272, 19875-19879.   DOI
22 Di Nisio, M., Middeldorp, S. and Buller, H. R. (2005) Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028-1040.   DOI
23 Eriksson, B. I., Quinlan, D. J. and Weitz, J. I. (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin. Pharmacokinet. 48, 1-22.   DOI
24 Esmon, C. T. (2005) The interactions between inflammation and coagulation. Br. J. Haematol. 131, 417-430.   DOI
25 Hirsh, J., O'Donnell, M. and Eikelboom, J. W. (2007) Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116, 552-560.   DOI
26 Hirsh, J. (1991) Heparin. N. Engl. J. Med. 324, 1565-1574.   DOI
27 Hirsh, J. (1998) Low-molecular-weight heparin. Circulation 98, 1575-1582.   DOI
28 Hirsh, J., Fuster, V., Ansell, J. and Halperin, J. L. (2003) American heart association/American college of cardiology foundation guide to warfarin therapy. J. Am. Coll. Cardiol. 41, 1633-1652.   DOI
29 Hirsh, J. and Fuster, V. (1994) Guide to anticoagulant therapy. Part I: heparin. Circulation. 89, 1449-1468.   DOI
30 Hirsh, J. and Raschke, R. (2004) Heparin and low-molecular-weight heparin: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126, 188S-203S.   DOI
31 Holmer, E., Soderberg, K., Bergqvist, D. and Lindahl, U. (1986) Heparin and its low molecular weight derivatives: Anticoagulant and antithrombotic properties. Haemostasis 16 Suppl 2, 1-7.
32 Hoppensteadt, D., Walenga, J. M., Fareed, J. and Bick, R. L. (2003) Heparin, low-molecular-weight heparins, and heparin pentasaccharide: Basic and clinical differentiation. Hematol. Oncol. Clin. North Am. 17, 313-341.   DOI
33 Howard, E. L., Becker, K. C. D., Rusconi, C. P. and Becker, R. C. (2007) Factor IXa inhibitors as novel anticoagulants. Arterioscler. Thromb. Vasc. Biol. 27, 722-727.   DOI
34 Kwon, I. S., Yim, J. H., Lee, H. K. and Pyo, S. (2016) Lobaric acid inhibits VCAM-1 expression in TNF-alpha-stimulated vascular smooth muscle cells via modulation of NF-kappaB and MAPK signaling pathways. Biomol. Ther. (Seoul) 24, 25-32.   DOI
35 Kearon, C., Comp, P., Douketis, J., Royds, R., Yamada, K. and Gent, M. (2005) Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J. Thrombo Haemost. 3, 962-968.   DOI
36 Kim, J. H., Lee, J., Kang, S., Moon, H., Chung, K. H. and Kim, K. R. (2016) Antiplatelet and antithrombotic effects of the extract of lindera obtusiloba leaves. Biomol. Ther. (Seoul) 24, 659-664.   DOI
37 Koster, A., Fischer, K. G., Harder, S. and Mertzlufft, F. (2007) The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT. Biologics 1, 105-112.
38 Kreimann, M., Brandt, S., Krauel, K., Block, S., Helm, C. A., Weitschies, W., Greinacher, A. and Delcea, M. (2014) Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 124, 2442-2449.   DOI
39 Krishnaswamy, A., Lincoff, A. M. and Cannon, C. P. (2010) The use and limitations of unfractionated heparin. Crit. Pathw. Cardiol. 9, 35-40.   DOI
40 Laterre, P. F., Opal, S. M., Abraham, E., LaRosa, S. P., Creasey, A. A., Xie, F., Poole, L. and Wunderink, R. G. (2009) A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Critic. Care 13, R36.   DOI
41 Lee, C. J. and Ansell, J. E. (2011) Direct thrombin inhibitors. Br. J. Clin. Pharmacol. 72, 581-592.   DOI
42 Hyers, T. M. (1999) Venous thromboembolism. Am. J. Respir. Crit. Care Med. 159, 1-14.   DOI
43 Merli, G. J. and Groce, J. B. (2010) Pharmacological and clinical differences between low-molecular-weight heparins: Implications for prescribing practice and therapeutic interchange. P. T. 35, 95-105.
44 Matyal, R., Mahmood, F. and Park, K. W. (2005) Tifacogin, recombinant tissue factor pathway inhibitor. Int. Anesthesiol. Clin. 43, 135-144.   DOI
45 Mega, J. L. and Simon, T. (2015) Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 386, 281-291.   DOI
46 Mekaj, Y. H., Mekaj, A. Y., Duci, S. B. and Miftari, E. I. (2015) New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther. Clin. Risk Manag. 11, 967-977.
47 Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B. and Eisenberg, M. J. (2012) Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardio. 110, 453-460.   DOI
48 Nawarskas, J. J. and Anderson, J. R. (2001) Bivalirudin: A new approach to anticoagulation. Heart Dis. 3, 131-137.
49 Park, J. M., Chang, K. H., Park, K. H., Choi, S. J., Lee, K., Lee, J. Y., Satoh M., Song S. Y. and Lee, M. Y. (2016) Differential effects between cigarette total particulate matter and cigarette smoke extract on blood and blood vessel. Toxicol. Res. 32, 353-358.   DOI
50 Piazza, G. and Goldhaber, S. Z. (2010) Venous thromboembolism and atherothrombosis: an integrated approach. Circulation 121, 2146-2150.   DOI
51 Previtali, E., Bucciarelli, P., Passamonti, S. M. and Martinelli, I. (2011) Risk factors for venous and arterial thrombosis. Blood Transfus. 9, 120-138.
52 Puurunen, M. K., Gona, P. N., Larson, M. G., Murabito, J. M., Magnani, J. W. and O'Donnell, C. J. (2016) Epidemiology of venous thromboembolism in the framingham heart study. Thromb. Res. 145, 27-33.   DOI
53 Rauova, L., Poncz, M., McKenzie, S. E., Reilly, M. P., Arepally, G., Weisel, J. W., Nagaswami, C., Cines, D. B. and Sachais, B. S. (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105, 131-138.   DOI
54 Rauova, L., Zhai, L., Kowalska, M. A., Arepally, G. M., Cines, D. B. and Poncz, M. (2006) Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107, 2346-2353.   DOI
55 Roser-Jones, C., Chan, M., Howard, E. L., Becker, K. C., Rusconi, C. P. and Becker, R. C. (2011) Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome. Cardiovasc. Ther. 29, e22-e35.   DOI
56 Stangier, J. and Clemens, A. (2009) Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin. Appl. Thromb. Hemost. 15 Suppl 1, 9S-16S.   DOI
57 Ruiz, F. A., Lea, C. R., Oldfield, E. and Docampo, R. (2004) Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J. Biol. Chem. 279, 44250-44257.   DOI
58 Ruppert, A., Lees, M. and Steinle, T. (2010) Clinical burden of venous thromboembolism. Curr. Med. Res. Opin. 26, 2465-2473.   DOI
59 Rupprecht, H. J. and Blank, R. (2010) Clinical pharmacology of direct and indirect factor Xa inhibitors. Drugs 70, 2153-2170.
60 Smith, S. A. and Morrissey, J. H. (2008) Polyphosphate enhances fibrin clot structure. Blood 112, 2810-2816.   DOI
61 Teitel, J. M. and Rosenberg, R. D. (1983) Protection of factor Xa from neutralization by the heparin-antithrombin complex. J. Clin. Invest. 71, 1383-1391.   DOI
62 Tollefsen, D. M., Majerus, D. W. and Blank, M. K. (1982) Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J. Biol. Chem. 257, 2162-2169.
63 Tran, H. A., Chunilal, S. D., Harper, P. L., Tran, H., Wood, E. M. and Gallus, A. S. (2013) An update of consensus guidelines for warfarin reversal. Med. J. Aust. 198, 198-199.   DOI
64 Butenas, S., Brummel, K. E., Branda, R. F., Paradis, S. G. and Mann, K. G. (2002) Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 99, 923-930.   DOI
65 Bea, F., Kreuzer, J., Preusch, M., Schaab, S., Isermann, B., Rosenfeld, M. E., Katus, H. and Blessing, E. (2006) Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 26, 2787-2792.   DOI
66 Bounameaux, H. and Camm, A. J. (2014) Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs 74, 1209-1231.   DOI
67 Bruni-Fitzgerald, K. R. (2015) Venous thromboembolism: an overview. J. Vasc. Nurs. 33, 95-99.   DOI
68 Buller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P. and Weitz, J. I. (2015) Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 372, 232-240.   DOI
69 Cabral, K. P. and Ansell, J. E. (2015) The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc. Health Risk Manage. 11, 117-123.
70 Abraham, E., Reinhart, K., Opal, S., Demeyer, I., Doig, C., Rodriguez, A. L., Beale, R., Svoboda, P., Laterre, P. F., Simon, S., Light, B., Spapen, H., Stone, J., Seibert, A., Peckelsen, C., De Deyne, C., Postier, R., Pettila, V., Sprung, C. L., Artigas, A., Percell, S. R., Shu, V., Zwingelstein, C., Tobias, J., Poole, L., Stolzenbach, J. C. and Creasey, A. A. (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial. JAMA 290, 238-247.   DOI
71 Garcia, D. A., Baglin, T. P., Weitz, J. I. and Samama, M. M. (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141, e24S-e43S.   DOI
72 Fareed, J., Hoppensteadt, D. A., Fareed, D., Demir, M., Wahi, R., Clarke, M., Adiguzel, C. and Bick, R. (2008) Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin. Thromb. Hemost. 34, 58-73.
73 Fitzmaurice, D. A., Blann, A. D. and Lip, G. Y. H. (2002) Bleeding risks of antithrombotic therapy. BMJ 325, 828-831.   DOI
74 Franchini, M., Liumbruno, G. M., Bonfanti, C. and Lippi, G. (2016) The evolution of anticoagulant therapy. Blood Transfus. 14, 175-184.
75 Fung, E., Patsopoulos, N. A., Belknap, S. M., O'Rourke, D. J., Robb, J. F., Anderson, J. L., Shworak, N. W. and Moore, J. H. (2012) Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin. Semin. Thromb. Hemost. 38, 893-904.
76 Gandhi, N. S. and Mancera, R. L. (2010) Heparin/heparan sulphatebased drugs. Drug Discov. Today 15, 1058-1069.   DOI
77 Greinacher, A., Thiele, T. and Selleng, K. (2015) Reversal of anticoagulants: an overview of current developments. Thromb. Haemost. 113, 931-942.   DOI
78 Hagedorn, I., Schmidbauer, S., Pleines, I., Kleinschnitz, C., Kronthaler, U., Stoll, G., Dickneite, G. and Nieswandt, B. (2010) Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121, 1510-1517.   DOI
79 Hardy, S., Schirm, S., Liu, X. and Dai, Y. (2006) Tifacogin increases bacterial clearance from blood. Crit. Care 10, P155.   DOI
80 Evans, H. C., Perry, C. M. and Faulas, D. (2004) Ximelagatran/melagatran. Drugs 64, 649-678.   DOI
81 Lurie, Y., Loebstein, R., Kurnik, D., Almog, S. and Halkin, H. (2010) Warfarin and vitamin K intake in the era of pharmacogenetics. Br. J. Clin. Pharmacol. 70, 164-170.   DOI
82 Hu, T. Y., Vaidya, V. R. and Asirvatham, S. J. (2016) Reversing anticoagulant effects of novel oral anticoagulants: Role of ciraparantag, andexanet alfa, and idarucizumab. Vasc. Health Risk Manag. 12, 35-44.
83 Heit, J. A., Spencer, F. A. and White, R. H. (2016) The epidemiology of venous thromboembolism. J. Thromb. Thrombolysis 41, 3-14.   DOI
84 Lee, D. H., Kim, H. H., Lim, D. H., Kim, J. L. and Park, H. J. (2015) Effect of cordycepin-enriched WIB801C from cordyceps militaris suppressing fibrinogen binding to glycoprotein IIb/IIIa. Biomol. Ther. (Seoul) 23, 60-70.   DOI
85 Lenting, P. J., van Mourik, J. A. and Mertens, K. (1998) The life cycle of coagulation factor VIII in view of its structure and function. Blood 92, 3983-3996.
86 Liaw, P. C., Becker, D. L., Stafford, A. R., Fredenburgh, J. C. and Weitz, J. I. (2001) Molecular basis for the susceptibility of fibrinbound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J. Biol. Chem. 276, 20959-20965.   DOI
87 Linkins, L. A., Choi, P. T. and Douketis, J. D. (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: A meta-analysis. Ann. Intern. Med. 139, 893-900.   DOI
88 Loke, C., Ali, S. S. and Johari, V. (2012) Pharmacology of anticoagulants. Dis. Mon. 58, 424-430.   DOI
89 Majeed, A. and Schulman, S. (2013) Bleeding and antidotes in new oral anticoagulants. Best Pract. Res. Clin. Haematol. 26, 191-202.   DOI
90 Mann, K. G., Brummel, K. and Butenas, S. (2003) What is all that thrombin for? J. Thromb. Haemost. 1, 1504-1514.   DOI
91 Marmur, J. D. (2002) Direct versus indirect thrombin inhibition in percutaneous coronary intervention. J. Invasive Cardiol. 14 Suppl B, 8B-18B.
92 Masuko, S. and Linhardt, R. J. (2012) Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics. Future Med. Chem. 4, 289-296.   DOI
93 Weitz, J. I., Hudoba, M., Massel, D., Maraganore, J. and Hirsh, J. (1990) Clot-bound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. 86, 385-391.   DOI
94 Pempe, E. H., Xu, Y., Gopalakrishnan, S., Liu, J. and Harris, E. N. (2012) Probing structural selectivity of synthetic heparin binding to stabilin protein receptors. J. Biol. Chem. 287, 20774-20783.   DOI
95 Perzborn, E., Roehrig, S., Straub, A., Kubitza, D. and Misselwitz, F. (2011) The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat. Rev. Drug Discov. 10, 61-75.   DOI
96 Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M. and Palareti, G. (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141, e44S-e88S.   DOI
97 Ahmed, Z., Hassan, S. and Salzman, G. A. (2016) Novel oral anticoagulants for venous thromboembolism with special emphasis on risk of hemorrhagic complications and reversal agents. Curr. Drug Ther. 11, 3-20.   DOI
98 Travers, R. J., Shenoi, R. A., Kalathottukaren, M. T., Kizhakkedathu, J. N. and Morrissey, J. H. (2014) Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 124, 3183-3190.   DOI
99 Walenga, J. M. and Lyman, G. H. (2013) Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. Crit. Rev. Oncol. Hematol. 88, 1-18.   DOI
100 Weitz, J. I. (1997) Low-molecular-weight heparins. N. Engl. J. Med. 337, 688-698.   DOI
101 Wessler, S. and Gitel, S. N. (1986) Pharmacology of heparin and warfarin. J. Am. Coll. Cardiol. 8, 10B-20B.   DOI
102 Wolzt, M., Weltermann, A., Nieszpaur-Los, M., Schneider, B., Fassolt, A., Lechner, K., Eichler, H. G. and Kyrle, P. A. (1995) Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man. Thromb. Haemost. 73, 439-443.
103 Wood, J. P., Ellery, P. E., Maroney, S. A. and Mast, A. E. (2014) Biology of tissue factor pathway inhibitor. Blood 123, 2934-2943.   DOI
104 Yeh, C. H., Fredenburgh, J. C. and Weitz, J. I. (2012) Oral direct factor Xa inhibitors. Circ. Res. 111, 1069-1078.   DOI